SWA
CTNM

Strategies Wealth Advisors’s Contineum Therapeutics CTNM Stock Holding History

Strategies Wealth Advisors’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$653K Hold
50,000
– – 0.07% 83
2025
Q4 		$572K Hold
50,000
– – 0.06% 87
2025
Q3 		$588K Hold
50,000
– – 0.06% 93
2025
Q2 		$199K Buy
50,000
+25,000
+100% +$109K 0.02% 178
2025
Q1 		$175K Hold
25,000
– – 0.02% 171
2024
Q4 		$206K Buy
+25,000
New +$396K 0.03% 121

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Strategies Wealth Advisors's CTNM Position: Q1 2026 in Review

Strategies Wealth Advisors held its Contineum Therapeutics (CTNM) position steady in Q1 2026 at 50,000 shares worth $653K. The position accounts for 0.07% of the portfolio, ranked #83.

Strategies Wealth Advisors first reported a position in CTNM in Q4 2024 and has held it in 6 quarters since. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Strategies Wealth Advisors held 50,000 shares of Contineum Therapeutics worth $653K as of Q1 2026.
  • Strategies Wealth Advisors left its Contineum Therapeutics share count unchanged in Q1 2026.
  • Contineum Therapeutics made up 0.07% of Strategies Wealth Advisors's portfolio in Q1 2026, its #83 holding.
  • Strategies Wealth Advisors first reported a position in Contineum Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Strategies Wealth Advisors's 13F filing for Q1 2026, filed 15 May 2026.